MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Cisplatin (Platinol ®)

Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.

Clinical Lung Cancer 2019 October 25 [Link] Paajanen J, Ilonen I, Lauri H, Järvinen T, Sutinen E, Ollila H, Rouvinen E, Lemström K, Räsänen J, Ritvos O, Koli K, Myllärniemi M Abstract BACKGROUND: Previous preclinical studies have shown that activin A is overexpressed in malignant pleural mesothelioma (MPM), associates with cancer cachexia, and is observed […]

November 28, 2019

Biomarkers, Chemotherapy, Cisplatin (Platinol ®), CT or CAT scan, Full Archive, Lung Cancer, Pleural
Comments Off on Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.

CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma.

Molecular Cancer Therapeutics 2019 November 6 [Link] Xu D, Liang SQ, Yang H, Bruggmann R, Berezowska S, Yang Z, Marti TM, Hall SRR, Gao Y, Kocher GJ, Schmid RA, Peng RW Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with dismal prognosis, largely due to poor response rates to and rapid relapse after first-line […]

November 18, 2019

Chemotherapy, Cisplatin (Platinol ®), Full Archive, Pemetrexed (Alimta), Pleural
Comments Off on CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma.

Modulation of Calretinin Expression in Human Mesothelioma Cells Reveals the Implication of the FAK and Wnt Signaling Pathways in Conferring Chemoresistance towards Cisplatin.

International Journal of Molecular Science 2019 October 29 [Link] Wörthmüller J, Salicio V, Oberson A, Blum W, Schwaller B Abstract Malignant mesothelioma (MM) is an aggressive asbestos-linked neoplasm, characterized by dysregulation of signaling pathways. Due to intrinsic or acquired chemoresistance, MM treatment options remain limited. Calretinin is a Ca2+-binding protein expressed during MM tumorigenesis that […]

November 12, 2019

Causation, Cisplatin (Platinol ®), Full Archive
Comments Off on Modulation of Calretinin Expression in Human Mesothelioma Cells Reveals the Implication of the FAK and Wnt Signaling Pathways in Conferring Chemoresistance towards Cisplatin.

Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.

Lancet Oncology 2019 October 15 [Link] Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crinò L, Krzakowski M, Rüssel J, Maconi A, Gianoncelli L, Grosso F Abstract BACKGROUND: Tumour Treating Fields (TTFields) are a regional, antimitotic treatment for solid tumours, which is based on […]

October 28, 2019

Chemotherapy, Cisplatin (Platinol ®), Full Archive, Pleural
Comments Off on Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.

Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.

Cancer Management and Research 2019 September 24 [Link] Walter RFH, Sydow SR, Berg E, Kollmeier J, Christoph DC, Christoph S, Eberhardt WEE, Mairinger T, Wohlschlaeger J, Schmid KW, Mairinger FD Abstract BACKGROUND: Bortezomib is an approved proteasome inhibitor for the treatment of certain lymphoma subtypes. Two clinical trials investigated bortezomib in patients with malignant pleural […]

October 10, 2019

Cisplatin (Platinol ®), Full Archive, Pleural
Comments Off on Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.

Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience.

Clinical Lung Cancer 2019 September 5 [Link] Franceschini D, De Rose F, Cozzi S, Renna I, Franzese C, Di Brina L, Navarria P, D’Agostino GR, Mancosu P, Tomatis S, Scorsetti M Abstract INTRODUCTION: We investigated the possible role of volumetric modulated arc therapy (VMAT) in the setting of adjuvant treatment of malignant pleural mesothelioma (MPM) […]

October 1, 2019

Carboplatin, Cisplatin (Platinol ®), Full Archive, Pleural, Pleurectomy/decortication, Radiotherapy
Comments Off on Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience.

Malignant Mesothelioma: Has Anything Changed?

Seminars in Respiratory and Critical Care Medicine 2019 June [Link] Kim RY1, Sterman DH2, Haas AR3 Abstract Malignant pleural mesothelioma is a rare cancer associated with asbestos exposure and portends a dismal prognosis. Its worldwide incidence has been increasing, and treatment options are currently suboptimal and noncurative. However, since the turn of the century, several […]

September 23, 2019

Cisplatin (Platinol ®), Environmental Asbestos Exposure, Full Archive, Occupational Asbestos Exposure, Pemetrexed (Alimta), Pleural
Comments Off on Malignant Mesothelioma: Has Anything Changed?

Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.

International Journal of Molecular Sciences 2019 August 26 [Link] Marcq E, Audenaerde JRV, Waele J, Jacobs J, Loenhout JV, Cavents G, Pauwels P, Meerbeeck JPV, Smits EL Abstract In light of the promising results of immune checkpoint blockade (ICPB) in malignant pleural mesothelioma (MPM), we investigated the effect of different chemotherapeutic agents on the expression […]

September 13, 2019

Chemotherapy, Cisplatin (Platinol ®), Epithelioid, Full Archive, Immune-based Therapies, Oxaliplatin (Eloxatin), Pemetrexed (Alimta), Pleural, Sarcomatoid
Comments Off on Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.

Multidisciplinary palliative treatment including isolated thoracic perfusion for progressive malignant pleural mesothelioma: a retrospective observational study.

Journal of B.U.O.N 2019 May-June [Link] Guadagni S, Masedu F, Zoras O, Zavattieri G, Aigner K, Guadagni V, Fumi L, Clementi M Abstract PURPOSE: To investigate the relative importance of isolated thoracic perfusion (ITP) in the multidisciplinary palliative treatment of progressive malignant pleural mesothelioma (MPM) patients. METHODS: Fifty-two MPM patients with progressive disease after systemic […]

September 9, 2019

Chemotherapy, Cisplatin (Platinol ®), Full Archive, Pemetrexed (Alimta), Pleural
Comments Off on Multidisciplinary palliative treatment including isolated thoracic perfusion for progressive malignant pleural mesothelioma: a retrospective observational study.

Pifithrin-μ induces necroptosis through oxidative mitochondrial damage but accompanies epithelial-mesenchymal transition-like phenomenon in malignant mesothelioma cells under lactic acidosis.

Archives of Pharmacal Research 2019 August 19 [Link] Abstract Heat shock protein 70 (HSP70), a chaperone protein associated with tumorigenesis and chemoresistance, has attracted significant attention as a potential therapeutic target for the development of anticancer drugs. Here, the effects of pifithrin-μ, an effective dual inhibitor of HSP70 and p53, on anticancer activities and epithelial-mesenchymal […]

September 3, 2019

Cisplatin (Platinol ®), Epithelioid, Full Archive, Gemcitabine (Gemzar), Pleural
Comments Off on Pifithrin-μ induces necroptosis through oxidative mitochondrial damage but accompanies epithelial-mesenchymal transition-like phenomenon in malignant mesothelioma cells under lactic acidosis.